Currently, there are approximately 25 drug targets under investigation for the treatment of PCa, including androgen receptor (AR), AR cofactors and regulators (such as NCOA1, NCOR1, TNK2, and others), androgen synthesis enzymes (e.g., CYP17), aurora A kinase, cyclin-dependent kinases (CDKs), growth factor receptors (EGFR, IGF1R, FGFR, VEGFR, MET), and tyrosine kinase (SRC) [5]. This evidence concerns the gene NCOA1 and posterior cortical atrophy.